Laurus Labs (LAURUSLABS) Aandelenoverzicht
Laurus Labs Limited, samen met haar dochterondernemingen, produceert en verkoopt geneesmiddelen en actieve farmaceutische ingrediënten (API's) in India en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 2/6 |
LAURUSLABS Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Laurus Labs Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,385.70 |
| 52 Week Hoogtepunt | ₹1,457.00 |
| 52 Week Laag | ₹641.05 |
| Bèta | 0.43 |
| 1 maand verandering | 9.39% |
| 3 maanden verandering | 32.37% |
| 1 Jaar Verandering | 104.85% |
| 3 jaar verandering | 285.99% |
| 5 jaar verandering | 123.97% |
| Verandering sinds IPO | 1,342.24% |
Recent nieuws en updates
Recent updates
LAURUSLABS: Future Returns Will Depend On Sustained Confidence In Higher P E Multiples
Analysts have lifted their fair value estimate for Laurus Labs stock to ₹1,044 from ₹913, reflecting updated assumptions around modestly higher revenue growth, improved profit margins and revised future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the higher fair value estimate as consistent with updated assumptions for Laurus Labs, where modestly higher revenue expectations support a richer long term P/E framework.
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Unsurprisingly, Laurus Labs Limited's ( NSE:LAURUSLABS ) stock price was strong on the back of its healthy earnings...
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Rendement voor aandeelhouders
| LAURUSLABS | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -0.6% | 1.2% | -0.7% |
| 1Y | 104.8% | 6.7% | -4.3% |
Rendement versus industrie: LAURUSLABS overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 6.7 % opleverde.
Rendement versus markt: LAURUSLABS overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van -4.3 %.
Prijsvolatiliteit
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stabiele aandelenkoers: LAURUSLABS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van LAURUSLABS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2005 | 6,167 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, samen met haar dochterondernemingen, produceert en verkoopt geneesmiddelen en actieve farmaceutische ingrediënten (API's) in India en internationaal. Het bedrijf biedt generieke API's aan voor geavanceerde tussenproducten voor de therapeutische gebieden antiretrovirale middelen (ARV), antidiabetica, cardiovasculaire middelen, middelen tegen astma, oogheelkunde, oncologie, gastro-enterologie en hepatitis C. Het biedt ook orale vaste formuleringen voor ARV's, antidiabetica, cardiovasculaire middelen, antidiabetica en hepatitis C. Het biedt ook vaste formuleringen voor oraal gebruik voor ARV's, antidiabetica, hart- en vaatziekten en PPI's. Daarnaast biedt het bedrijf organisatorische diensten op het gebied van contractontwikkeling en -productie en biotechnologische diensten voor nutraceutica, voedingssupplementen, alternatieve voedseleiwitten en cosmeceutische producten.
Laurus Labs Limited Samenvatting
| LAURUSLABS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹748.08b |
| Inkomsten(TTM) | ₹8.89b |
| Inkomsten(TTM) | ₹68.13b |
Is LAURUSLABS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LAURUSLABS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹68.13b |
| Kosten van inkomsten | ₹26.95b |
| Brutowinst | ₹41.17b |
| Overige uitgaven | ₹32.29b |
| Inkomsten | ₹8.89b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 16.46 |
| Brutomarge | 60.44% |
| Nettowinstmarge | 13.05% |
| Schuld/Eigen Vermogen Verhouding | 44.1% |
Hoe presteerde LAURUSLABS op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/10 17:06 |
| Aandelenkoers aan het einde van de dag | 2026/06/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Laurus Labs Limited wordt gevolgd door 22 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |